Cargando…

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-dose TKI (HD-TKI) pulse-exposure is sufficient to irreve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipka, Daniel B., Wagner, Marie-Christine, Dziadosz, Marek, Schnöder, Tina, Heidel, Florian, Schemionek, Mirle, Melo, Junia V., Kindler, Thomas, Müller-Tidow, Carsten, Koschmieder, Steffen, Fischer, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397954/ https://www.ncbi.nlm.nih.gov/pubmed/22815843 http://dx.doi.org/10.1371/journal.pone.0040853

Ejemplares similares

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
por: Langhammer, Melanie, et al.
Publicado: (2023)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
por: Jacobi, Henrike, et al.
Publicado: (2023)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Frequency of BCR-ABL Transcript Types in Syrian CML Patients
por: Farhat-Maghribi, Sulaf, et al.
Publicado: (2016)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

Loss of Gadd45b accelerates BCR-ABL-driven CML
por: Sha, Xiaojin, et al.
Publicado: (2018)

IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML
por: Gaballa, Salem, et al.
Publicado: (2020)

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
por: Herrmann, Oliver, et al.
Publicado: (2019)

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias
por: Lipka, D B, et al.
Publicado: (2016)

Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
por: Agarwal, Mohan B.
Publicado: (2014)

Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors
por: Minami, Y, et al.
Publicado: (2012)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
por: Burchert, Andreas
Publicado: (2014)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020)

Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CML
por: Lima, Maria Carolina P., et al.
Publicado: (2023)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
por: Zizioli, Daniela, et al.
Publicado: (2021)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing
por: Kirschner, Martin M. J., et al.
Publicado: (2015)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients
por: Gaafar, Taghrid Mohamed, et al.
Publicado: (2015)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023)

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
por: Bennett, John M., et al.
Publicado: (2014)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
por: Virgili, Anna, et al.
Publicado: (2010)

ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance
por: Wang, Zhiqiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pcp1e54p4i19vjkdngmavq9fa1